NCT00892775View on ClinicalTrials.gov

Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds

PHASE2CompletedINTERVENTIONAL
Enrollment

501

Participants

Timeline

Start Date

June 3, 2009

Primary Completion Date

September 17, 2010

Study Completion Date

December 13, 2010

Conditions
MeaslesVaricellaMumpsRubella
Interventions
BIOLOGICAL

Priorix-Tetra (combined measles-mumps-rubella-varicella vaccine)

Vaccine will be administered subcutaneously in the left upper arm (deltoid region)

BIOLOGICAL

GSK Biologicals' 208136, new formulation

Vaccine will be administered subcutaneously in the left upper arm (deltoid region)

Trial Locations (6)

100

GSK Investigational Site, Taipei

104

GSK Investigational Site, Taipei

119074

GSK Investigational Site, Singapore

228510

GSK Investigational Site, Singapore

229899

GSK Investigational Site, Singapore

Unknown

GSK Investigational Site, Taipei

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY